RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 62 filers reported holding RA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $804,000 | -67.9% | 16,750 | -68.7% | 0.00% | -50.0% |
| Q4 2019 | $2,507,000 | +198.8% | 53,436 | +50.2% | 0.00% | +100.0% |
| Q3 2019 | $839,000 | -46.4% | 35,579 | -31.7% | 0.00% | 0.0% |
| Q2 2019 | $1,565,000 | -64.7% | 52,090 | -73.7% | 0.00% | -66.7% |
| Q1 2019 | $4,428,000 | +266.6% | 197,741 | +197.7% | 0.00% | +200.0% |
| Q4 2018 | $1,208,000 | -64.1% | 66,433 | -64.3% | 0.00% | 0.0% |
| Q3 2018 | $3,364,000 | +94.8% | 186,046 | +7.1% | 0.00% | – |
| Q2 2018 | $1,727,000 | +44.0% | 173,757 | -23.1% | 0.00% | -100.0% |
| Q1 2018 | $1,199,000 | +435.3% | 225,952 | +755.1% | 0.00% | – |
| Q4 2017 | $224,000 | -39.5% | 26,425 | +3.6% | 0.00% | – |
| Q3 2017 | $370,000 | -27.2% | 25,504 | -6.1% | 0.00% | – |
| Q2 2017 | $508,000 | +29.6% | 27,165 | +47.0% | 0.00% | – |
| Q1 2017 | $392,000 | -9.3% | 18,483 | -35.5% | 0.00% | – |
| Q4 2016 | $432,000 | – | 28,635 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $288,094,000 | 13.62% |
| RA Capital Management | 4,858,260 | $227,998,000 | 6.91% |
| HAVENS ADVISORS LLC | 116,000 | $5,444,000 | 4.77% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,115,600 | $99,286,000 | 3.16% |
| SYQUANT CAPITAL SAS | 129,690 | $6,086,000 | 3.13% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 391,758 | $18,386,000 | 3.02% |
| Kellner Capital, LLC | 91,100 | $4,275,000 | 2.71% |
| Telemetry Investments, L.L.C. | 17,100 | $803,000 | 2.68% |
| Versor Investments LP | 1,002,649 | $47,054,000 | 2.38% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,519,718 | $71,320,000 | 2.28% |